---
document_datetime: 2025-12-04 09:49:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/paxlovid-epar-scientific-conclusions-request-one-year-marketing-protection-presented-european-medicines-agency_en.pdf
document_name: paxlovid-epar-scientific-conclusions-request-one-year-marketing-protection-presented-european-medicines-agency_en.pdf
version: success
processing_time: 0.4642889
conversion_datetime: 2025-12-27 15:52:35.994132
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex IV

Conclusions on the request for one-year marketing protection presented by the European Medicines Agency

<div style=\"page-break-after: always\"></div>

## Conclusions presented by the European Medicines Agency on:

## Â· one-year marketing protection

The CHMP reviewed the data submitted by the marketing authorisation holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.